HSIEN-YI CHIUHsieh C.-F.Chiang Y.-T.Huang W.-F.TSEN-FANG TSAI2022-01-112022-01-1120161932-6203https://www.scopus.com/inward/record.uri?eid=2-s2.0-84982706273&doi=10.1371%2fjournal.pone.0160041&partnerID=40&md5=c12184d8e06ada68edbc466c0d721be8https://scholars.lib.ntu.edu.tw/handle/123456789/592068Background Psoriasis is a chronic systemic inflammatory disorder, and studies have revealed its association with a variety of comorbidities. However, the risk of chronic pancreatitis (CP) in psoriasis has not been studied. This study aimed to investigate the risk of CP among patients with psoriasis. Methods Using the Taiwan National Health Insurance Research Database, this population-based cohort study enrolled 48430 patients with psoriasis and 193720 subjects without psoriasis. Stratified Cox proportional hazards models were used to compare the risks of CP between the patients with and without psoriasis. Results The incidence of CP was 0.61 per 1000 person-years in patients with psoriasis and 0.34 per 1000 person-years in controls during a mean 6.6-year follow-up period. Before adjustment, patients with psoriasis had a significantly higher risk of CP (crude hazard ratio (HR) = 1.81; 95% confidence interval (CI) = 1.53-2.15), and the risk remained significantly higher after adjustments for gender, age group, medications, and comorbidities (adjusted HR (aHR) = 1.76; 95% CI = 1.47-2.10). All psoriasis patient subgroups other than those with arthritis, including those with mild and severe psoriasis and those without arthritis, had significantly increased aHRs for CP, and the risk increased with increasing psoriasis severity. Psoriasis patients taking nonsteroidal anti-inflammatory drugs (aHR = 0.33; 95% CI = 0.22-0.49) and methotrexate (aHR = 0.28; 95% CI = 0.12-0.64) had a lower risk of developing CP after adjustments. Conclusions Psoriasis is associated with a significantly increased risk of CP. The results of our study call for more research to provide additional insight into the relationship between psoriasis and CP.his study was supported in part by a grant from National Taiwan University Hospital, Hsin-Chu Branch (grant number: 105-HCH005; https://www. hch.gov.tw/english/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. ? 2016 Chiu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.[SDGs]SDG3adalimumab; azathioprine; cyclophosphamide; cyclosporin; etanercept; etretin; hydroxyurea; methotrexate; nonsteroid antiinflammatory agent; adult; age; aged; arthritis; Article; cardiovascular disease; cholelithiasis; chronic kidney disease; chronic obstructive lung disease; chronic pancreatitis; cohort analysis; comorbidity; controlled study; diabetes mellitus; disease association; disease severity; drug use; female; follow up; gender; hepatitis B; hepatitis C; human; hypertension; hypertriglyceridemia; incidence; major clinical study; male; middle aged; obesity; outcome assessment; patient risk; population research; psoriasis; retrospective study; Taiwan; tobacco dependence; adolescent; chronic disease; complication; health survey; pancreatitis; psoriasis; young adult; Adolescent; Adult; Aged; Chronic Disease; Cohort Studies; Female; Humans; Male; Middle Aged; Pancreatitis; Population Surveillance; Psoriasis; Taiwan; Young Adultjournal article10.1371/journal.pone.0160041274672652-s2.0-84982706273